Xconomy: New York Biotech – How to make it here
6:15-6:45 PM | The Rgenix Story: From our beginnings as a small spin-out from Rockefeller University to a world-class team with multiple clinical programs and $40M in Series C funding, our executives tell the story of our Manhattan-based biotechnology company. Masoud Tavazoie - CEO,
Rgenix CEO Masoud Tavazoie Discusses Immune System Regulation in Cancer at Plenary Session during AACR Meeting
On November 28, 2018, Masoud Tavazoie, Co-Founder and CEO of Rgenix, made a presentation at AACR’s Tumor Immunology and Immunotherapy conference in Miami, Fl. As part of his presentation, Masoud described the LXR/ApoE pathway and its role in regulating the innate
AACR Tumor Immunology and Immunotherapy Conference
AACR Tumor Immunology and Immunotherapy Conference November 27 - 30, 2018 | Loews Miami Beach Hotel, Miami Beach, Florida, USA Wednesday, Nov. 28 - Plenary Session 3: Metabolic Regulation in Tumors: Implications for Therapy Session Chair: Matthew G. Vander Heiden, David H. Koch Institute
Rgenix Treats First Patient in Phase 1 Trial of RGX-202
NEW YORK – Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, today announced it has treated the first patient in a Phase 1 a/b study of RGX-202, an oral small molecule being developed for the
Rgenix Raises $40M in Series C Funding To Support Clinical Stage Oncology Programs
Lepu Holdings Limited leads the financing syndicate and is joined by existing major investors Novo Holdings A/S and Sofinnova Partners New York, NY – October 9, 2018 — Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer